Health

FDA Grants Interchangeable Designation to Yuflyma (adalimumab-aaty), Celltrion's Biosimilar to Humira (adalimumab)

DailyTrendDailyTrend
Apr 15, 2025 - 17:00
 0  1
FDA Grants Interchangeable Designation to Yuflyma (adalimumab-aaty), Celltrion's Biosimilar to Humira (adalimumab)
INCHEON, South Korea, April 14, 2025 /-- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated Yuflyma (adalimumab-aaty), as an interchangeable biosimilar to Humira (adalimumab). Yuflyma is an FDA-approved...
Read More

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
DailyTrend
DailyTrend

Related Posts

Trump Announces Health Care Records System for Consumers

Trump Announces Health Care Records System for Consumers

DailyTrend Jul 31, 2025  0  0

FDA Approves Vizz (aceclidine ophthalmic solution) for the Treatment of Presbyopia

FDA Approves Vizz (aceclidine ophthalmic solution) for ...

DailyTrend Aug 4, 2025  0  0

Radioactive Wasps Found at Nuclear Site in South Carolina Could Be a ‘Red Flag,’ Expert Says

Radioactive Wasps Found at Nuclear Site in South Caroli...

DailyTrend Aug 1, 2025  0  0

For Some, Return of Presidential Fitness Test Revives Painful Memories

For Some, Return of Presidential Fitness Test Revives P...

DailyTrend Aug 2, 2025  0  0

US FDA Approves New Biktarvy Indication For People With HIV Who Are Treatment Experienced And Restarting Antiretroviral Treatment

US FDA Approves New Biktarvy Indication For People With...

DailyTrend Aug 2, 2025  0  0

Susan Monarez Faces Daunting Challenges as C.D.C. Director

Susan Monarez Faces Daunting Challenges as C.D.C. Director

DailyTrend Aug 1, 2025  0  0